GET DAILY SIGNALSStevanato Group (STVN) Falls -28% in 30 Days as GLP-1 Outlook Shifts
Key Takeaways
- Stevanato Group (STVN) shares fell roughly 28% over the trailing 30 days, with the bulk of the decline occurring in a single trading session after its third-quarter 2026 report.
- Third-quarter revenue rose 8% to €326.1 million and adjusted diluted EPS of €0.16 matched consensus, but forward commentary on GLP-1 demand pressured the stock.
- Management now expects lower GLP-1-related volumes and revenue in 2027, forecasting only low single-digit growth next year as injectable GLP-1 demand moderates.
- Demand for non-GLP-1 biologic products grew more than 30% in the quarter, partially offsetting a 12% decline in the Engineering segment.
- Full-year 2026 guidance was reaffirmed, including revenue of €1.26–€1.28 billion and adjusted diluted EPS of €0.60–€0.62.
Stevanato Group’s Business and Market Role
Stevanato Group S.p.A. is an Italy-based provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. Founded in 1949, the company supplies glass vials, cartridges, syringes, and related drug delivery systems, along with engineering and equipment services, across the entire drug life cycle from development through commercial manufacturing.
Stevanato is closely followed by investors because of its exposure to the fast-growing injectable biologics market, including GLP-1 therapies used in diabetes and obesity treatment. Its integrated, end-to-end model and high-value solutions strategy have helped it build a global customer base, but the company's results are also sensitive to shifts in customer demand, particularly within the GLP-1 category. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
STVN Stock Price Performance Over the Past 30 Days and Quarter
Over the trailing 30 days, STVN shares declined approximately 28%, falling from a closing price near $20 in early October to an intraday level around $14.50 following its third-quarter earnings release. The move was abrupt rather than gradual, with the stock shedding more than 25% in a single session as investors reassessed the company's growth outlook.
The quarterly trend has been similarly negative. Since early August, when shares traded near $20.50, the stock has declined roughly 30%, erasing the gains built during the summer. The broader pattern reflects a rotation away from injectable GLP-1 exposure as concerns about a demand slowdown and oral alternatives weighed on sentiment.
What Drove the Recent 30-Day Move in STVN
The defining catalyst was Stevanato's third-quarter 2026 report released on November 3. While headline results were broadly in line with expectations — revenue of €326.1 million, up 8% year over year, and adjusted diluted EPS of €0.16 — the forward-looking commentary triggered a sharp sell-off.
Chief Executive Officer Franco Stevanato said the company now anticipates lower GLP-1-related volumes and revenue in 2027 than previously projected, which is expected to cause a temporary moderation of growth next year. Management guided for low single-digit growth in 2027, a meaningful step down from the double-digit expansion investors had come to expect from the GLP-1 opportunity.
The company reiterated its full-year 2026 outlook — revenue of €1.26–€1.28 billion, adjusted EBITDA of €335.0–€345.2 million, and adjusted diluted EPS of €0.60–€0.62 — but the 2027 caution overshadowed the confirmation. GLP-1 therapies represented roughly 17%–18% of third-quarter revenue, while non-GLP-1 biologic demand grew more than 30%, and the Engineering segment declined 12%. Weaker-than-expected GLP-1 momentum, combined with lingering concerns about oral alternatives to injectable therapies, drove the repricing. From what I see, this earnings reaction highlights how sensitive the valuation remains to any shift in the GLP-1 narrative.
Factors Behind the Quarterly Decline
The quarterly decline reflects a broader narrative shift rather than a single event. Through the summer, Stevanato shares rallied into the low-$20s as investors positioned around strong GLP-1 demand and improving margins. In the third quarter, adjusted EBITDA margin expanded 150 basis points to 27.2%, and high-value solutions represented 46% of total revenue, underscoring underlying operational momentum.
However, sentiment deteriorated as the market began pricing in a slower GLP-1 trajectory. Analyst actions over recent months reflected growing caution, with several firms lowering price targets and maintaining neutral ratings. Insider selling activity added further pressure, and the November earnings release crystallized the concern by formalizing management's expectation of a 2027 growth slowdown. The result was a sustained de-rating from the summer highs.
Key Areas to Monitor Going Forward
Investors should monitor how GLP-1 demand trends evolve in the coming quarters, as management's 2027 outlook hinges on the pace of that slowdown. The growth of non-GLP-1 biologic products will be another key variable, given the company's progress in offsetting GLP-1 weakness with a broader product mix. The Engineering segment's recovery also remains a focus after its double-digit revenue decline.
Beyond company-specific factors, watch for further analyst revisions, changes to pricing or demand guidance, and developments in oral GLP-1 therapies that could affect injectable drug delivery volumes. Macroeconomic conditions and capital spending trends across the pharmaceutical industry may also influence results. These are areas to observe, not a basis for specific investment decisions. I’m watching this closely as the 2027 guidance becomes clearer in future updates.
Reviewing AI Trading Bots for Additional Perspective
When reviewing stocks facing similar demand shifts, I find it useful to look at how automated strategies are positioned. Tickeron’s Trending AI Robots page offers a selection of algorithmic trading strategies that monitor thousands of tickers. These tools help surface different approaches based on performance and relevance, providing one more lens for evaluating market conditions without replacing individual analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STVN's Indicator enters downward trend
The Aroon Indicator for STVN entered a downward trend on October 27, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator formed such a pattern. In 154 of the 172 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 64 cases where STVN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
STVN moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for STVN crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
STVN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STVN's RSI Oscillator exited the oversold zone, 22 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on STVN as a result. In 80 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for STVN just turned positive on October 23, 2026. Looking at past instances where STVN's MACD turned positive, the stock continued to rise in 52 of 56 cases over the following month. The odds of a continued upward trend are 90%.
Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where STVN advanced for three days, in 242 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. STVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.479) is normal, around the industry mean (4.877). P/E Ratio (40.286) is within average values for comparable stocks, (37.682). Projected Growth (PEG Ratio) (1.538) is also within normal values, averaging (4.143). Dividend Yield (0.003) settles around the average of (0.005) among similar stocks. P/S Ratio (4.348) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther